What is NephroPlus?
NephroPlus operates as India's largest network of dialysis centers, fundamentally altering the patient experience by prioritizing quality care and reducing the stress associated with chronic renal treatment. The company has successfully spearheaded a shift in the dialysis market, moving away from fragmented, low-quality offerings toward a standardized, high-efficiency model. By integrating advanced clinical protocols with a scalable operational framework, NephroPlus has established a defensible market position that addresses the critical demand for accessible, life-sustaining medical services across the subcontinent.
How much funding has NephroPlus raised?
NephroPlus has raised a total of $155.1M across 5 funding rounds:
Series A
$4.3M
Series B
$10M
Series C
$15M
Series E
$24M
Series F
$101.8M
Series A (2011): $4.3M with participation from Bessemer Venture Partners
Series B (2014): $10M led by International Finance Corporation and Bessemer Venture Partners
Series C (2016): $15M supported by International Finance Corp and SeaLink Capital Partners
Series E (2021): $24M featuring IIFL Asset Management, Investcorp, and Bessemer Venture Partners
Series F (2024): $101.8M backed by Quadria Capital Investment Management
Key Investors in NephroPlus
Quadria Capital Investment Management
Quadria Capital is a leading private equity firm based in India and Singapore, focused on transforming healthcare in Asia through strategic investments in scalable healthcare companies.
International Finance Corp
International Finance Corporation operates as a multilateral financial institution dedicated to mobilizing capital and expertise for sustainable development across emerging markets.
Bessemer Venture Partners
Bessemer Venture Partners is a global venture capital firm with a long history of supporting innovative companies across various sectors, including healthcare and technology.
What's next for NephroPlus?
With the successful closure of this major strategic investment, NephroPlus is well-positioned to accelerate its expansion efforts and deepen its technological integration within the dialysis ecosystem. The company's strategic roadmap likely involves further geographic penetration and the enhancement of its digital health platforms to improve patient outcomes and operational efficiency. As the firm moves into this next phase of maturity, the focus will remain on leveraging its substantial capital reserves to optimize service delivery, invest in specialized medical talent, and potentially explore adjacent healthcare verticals that complement its core renal care expertise. This trajectory suggests a continued emphasis on sustainable growth and long-term value creation for its stakeholders.
See full NephroPlus company page
